DeepMind founder Demis Hassabis, a 2024 Nobel Laureate in Chemistry, recently predicted that within the next ten years, AI will help cure almost any disease. If he's right, we're not just looking at medical breakthroughs; we're facing a fundamental shift in how economies handle aging populations, healthcare spending, and human longevity itself.

The prediction might sound like science fiction, but economists and researchers are taking it seriously enough to model what happens if it comes true. The question isn't just whether AI can do it, but what the world looks like when it does.

How Is AI Actually Speeding Up Drug Discovery?

Traditional drug development is painfully slow. It takes an average of more than a decade to develop a new medication, and costs often reach hundreds of millions of dollars. The process feels like searching for a needle in a haystack, with researchers testing thousands of compounds through years of lab work and clinical trials.

AI is fundamentally changing this by moving biology from test tubes to computers. Instead of physically testing drug candidates on cells, then animals, then humans, researchers can now build advanced "digital twins" of human cells and organs. AI can then run millions of simulations on these digital models before a single molecule is even manufactured in the real world. This approach could compress drug development timelines from over a decade to just a few months.

The breakthrough that illustrates this power is AlphaFold, an AI system that predicts how proteins fold in three dimensions. Proteins are the building blocks of life, and understanding their shape is crucial for how they function and interact with other substances. Before AlphaFold, human researchers worldwide had spent 60 years mapping just 0.1 percent of the more than 200 million proteins that exist. AlphaFold mapped the remaining 99.9 percent in less than a year.

What Would a Disease-Free Decade Actually Look Like?

If Hassabis's timeline holds, the economic implications are staggering. Today, the world's population is about 8.2 billion, growing by roughly 75 million people annually. In the most extreme scenario, if almost no one dies from disease while birth rates stay constant, annual population growth would jump from 75 million to 135 million people per year. After ten years, the global population would reach just over 9.5 billion.

That sounds alarming, but it's actually less dramatic than it appears. The United Nations currently forecasts the world population will reach around 8.9 billion by the mid-2030s. Even under the extreme disease-elimination scenario, we'd have time to address population concerns before they become critical.

The real economic story, however, isn't about overpopulation. It's about what happens when people stay healthy longer.

How Would Healthcare Systems Actually Change?

In traditional economic thinking, older people are viewed as dependent on society because they no longer work and consume most healthcare resources. But in a world without widespread disease, that entire framework collapses. The line between "working age" and "retired" would blur significantly.

Research by Andrew J. Scott, an economics professor at London Business School, suggests there are enormous financial benefits from extending healthy life expectancy. His calculations show that adding just one year to healthy life expectancy is worth about 3 to 4 percent of GDP annually for a country like the United States. This comes from a combination of reduced healthcare costs and increased productivity.

Consider the practical implications:

• Workforce Extension: Experienced, highly educated 75-year-olds could continue working or running businesses with the energy and mental capacity of their younger selves, dramatically increasing productive output.
• Healthcare Budget Reallocation: The health sector, which today consumes over 10 percent of GDP in Western countries, could be redirected to education, infrastructure, or other priorities.
• Prevention Over Treatment: Instead of spending years managing chronic diseases like dementia or cancer, healthcare systems could focus on preventing disease altogether, fundamentally reducing total costs.

One of the biggest threats to modern welfare states today isn't that people live too long, but that they live too long in poor health. AI-designed preventive medications could shorten that period significantly.

Will Only the Wealthy Get Access to AI-Designed Drugs?

A common dystopian worry is that revolutionary AI treatments will be available only to tech billionaires. But there are strong economic reasons why this is unlikely. Once a treatment has been discovered, the expensive part is already done. The actual production of AI-designed molecules is cheap, and the marginal cost of manufacturing them is usually low.

Governments and healthcare systems have strong financial incentives to distribute these treatments widely. The cost of providing a population with AI-designed preventive medications would likely be a fraction of what it costs to provide years of chronic disease care. History also shows that medical advances quickly become mass products. Antibiotics, vaccines, and other breakthrough treatments eventually reached billions of people globally.

However, there's a historical pattern worth noting: new medical technology has almost always driven up total healthcare costs over time as we find new conditions to treat and enable people to live longer in poor health. For AI to break this trend, the technology must succeed in preventing disease altogether, rather than just prolonging treatment pathways.

Could We Actually Achieve "Eternal Life"?

Some researchers discuss a concept called Longevity Escape Velocity (LEV). It means medical science extends remaining lifespan faster than time passes. If research manages to add more than 12 months to life expectancy every year, you theoretically reach a point where you could live indefinitely.

But most gerontologists and researchers believe true eternal life remains far away. Instead, the more realistic scenario is that people will continue to age, but experience significantly less illness and frailty in their final 15 to 20 years. The focus shifts from extending life at any cost to extending healthy life.

"If we hypothetically assume that Demis Hassabis is right, what kind of development are we facing? Does this even mean that 'everlasting life' is within reach?" noted Johan Javeus, senior economist at SEB, in his analysis of AI's potential impact on longevity.

Johan Javeus, Senior Economist at SEB

The timeline matters enormously for who benefits. Today's young people, including Generation Z and Generation Alpha, may be the first to face the actual choice of how long they want to live. But even those approaching retirement age today could see significant health improvements if Hassabis's ten-year prediction holds.

The convergence of AI protein folding, digital simulation, and computational drug design suggests that the next decade could fundamentally reshape medicine, economics, and human longevity itself. Whether Hassabis's prediction proves accurate, the trajectory is clear: AI is moving biology from the realm of slow, expensive experimentation into the realm of fast, cheap computation.